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Osteosarcoma is the most frequent malignant bone neoplasm, followed by
chondrosarcoma and Ewing sarcoma. The diagnosis of bone neoplasms is generally
made through histological evaluation of a biopsy. Clinical and radiological features
are also important in aiding diagnosis and to complete the staging of bone cancer.
In addition to these, there are several non-specific serological or specific molecular
markers for bone neoplasms. In bone tumors, molecular markers increase the accuracy
of the diagnosis and assist in subtyping bone tumors. Here, we review these
markers and discuss their role in the diagnosis and prognosis of the three most
frequent malignant bone neoplasms, namely osteosarcoma, chondrosarcoma, and
Ewing sarcoma.
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INTRODUCTION
Neoplastic bone disease includes metastatic lesions and primary bone neoplasms. We divide
primary bone neoplasms into two groups: benign and malignant bone neoplasms.
Primary malignant bone neoplasms are quite rare and account for 0.2% of all human neoplasms.
The incidence of primary malignant bone sarcomas compared with that of soft tissue sarcomas
shows that osseous neoplasms are approximately 1/10 of their soft tissue counterparts (Fletcher
et al., 2002).
According to the SEER registry, from 2005 to 2009, on average, the diagnosis of cancer is made
around 41 years. Approximately, 54.5% were diagnosed in under 44-year-olds (28.2% under 20)
and 32.2% in over 55-year-olds. Annually, the incidence rate was 0.9 per 100,000. In the US, the
median age at death for bone cancer is 58 years. Approximately, 28.3% died under 34 years. The
mortality for year is 0.4 per 100,000 (patients who died in 2005–2009 in the US) (Howlader et al.,
2002).
Osteosarcoma is the most frequent malignant bone neoplasm (36% of cases), followed by
chondrosarcoma (20–25%) and Ewing sarcoma (16%).
The etiology of malignant bone cancers is largely unknown. Some precancerous conditions,
e.g., Paget disease, radiation injury and benign cartilaginous dysplasia’s have been identified, and
recognizable syndromes with a high risk of malignant degeneration have been described (Ollier
disease, Maffucci syndrome), although the majority of primary bone cancers arise de novo (Fletcher
et al., 2002).
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The clinical presentation of bone tumors is non-specific.
Pain, swelling and general discomfort are the most common
symptoms. Pathologic fractures are often tardive manifestations
of the disease. Other clinical features include: limitation of
movement, hyperthermia of the skin, loss of weight and alteration
of anatomic profile with a visible mass (Singer and David, 2008;
Jawad and Scully, 2010; Szuhai et al., 2012).
The diagnosis of bone neoplasms is histological, through
a biopsy. Clinical and radiological features are important to
integrate diagnostic algorithms and to complete the staging of
bone cancer. Tumor staging, for prognostic purposes, includes
the degree of differentiation and the local and distant diffusion.
The biological classification allows to evaluate the behavior of
the malignant lesion. There are different grading systems with
two (TNM two grade system), three or four grades. The higher
the grade, the more aggressive is the cancer. The classification
of sarcomas is based on criteria of Broders (1920) for grading
squamous cell carcinoma (Fletcher et al., 2002).
In order to stage a neoplasm, we consider the grading together
with other parameters such as local extension, and lymphonodal
and distant metastasis. There are different staging systems based
on clinical, radiological and histological features.
The TNM staging system is also valid for bone neoplasm, but is
not commonly used because sarcomas do not usually metastasize
to lymph nodes.
The Enneking surgical staging system for malignant
mesenchymal tumors takes into account the surgical grade
(G, G1, G2), local extent (T, T1, T2), and presence or absence of
metastasis (M0, M1).
The staging system for malignant musculoskeletal sarcomas
consists of three stages. Stage III represents any tumor with
distant metastasis. Stages I and II are based on surgical grade of
the tumor. Each stage is further divided into two subcategories
(A, B) based on the local extent of the tumor. This last parameter,
i.e., localization, is not taken into account by the Enneking system
and represents one of its limits.
While the role of radiology and histology in the diagnosis,
prognosis and treatment of bone neoplasm has been well-defined
for several years, the role of biochemical markers (serum, genetic
or histological markers) is still unclear.
The purpose of this review is to focus on these markers
and, based on the literature of the last 5 years, to discuss
their real function in the diagnosis and prognosis of the
three most frequent malignant bone neoplasms: osteosarcoma,
chondrosarcoma, and Ewing sarcoma.
BIOMARKERS
There are several biomarkers and these can be specific or
aspecific; diagnostic, prognostic, or therapeutic; serological,
genetic, or histological. In accord with Joerger M, Huober J, and
extending their discussion of bone turnover markers to markers
in general, “the use of markers in oncology includes monitoring
treatment in patients with malignant disease (therapeutic
monitoring), predicting the risk of bone relapse in patients with
a first diagnosis of potentially curative, early-stage malignant
tumors (prognostic use), and making an early diagnosis of
(microscopic) malignant bone disease in patients with a known
malignant tumor to start early bone-targeted treatment and avoid
skeletal-related events (diagnostic use)” (Joerger and Huober,
2012).
Serological (Bone Formation and
Resorption) Biomarkers
This group includes a series of serological markers which
reflect the osteoblastic and osteoclastic activity of the bone.
They can have diagnostic and prognostic value and can be
useful in monitoring therapies, although there are no guidelines
recommending their use in clinical practice. Their levels can alter
under different conditions, physiological or pathological, and
thus they are not specific.
In cancer, Biochemical markers are useful to evaluate the
dissemination a distance, the response to therapy and survival.
Metastases can be classified, based on radiological features, as
osteolytic, osteoblastic, or mixed. The osteoblastic lesions are
manifested by high levels of bone turnover markers. High levels
of these markers again predict poor prognosis (Singer and David,
2008).
The use of bone markers in malignant tumors allows an early
diagnosis, fast start of therapy, limited complications and predict
the risk of relapse in patients with early-stage malignant tumors
(Joerger and Huober, 2012).
In patients with osteolytic lesions, Elevated levels of urinary
NTx causes a greater risk of complications and progression of
cancer (Singer and David, 2008).
There is limited evidence that bone turnover markers
can be used to predict bone metastases in patients with
early-stage malignant tumors, with PINP (N-terminal propeptide
of type 1 procollagen), ICTP (carboxyterminal cross-linked
telopeptide of type I collagen) and bone sialoprotein (BSP), with
tumor immunoexpression of BSP being the most studied and
discussed. In the diagnostic process, serum bone-specific alkaline
phosphatise (BSAP), PINP and osteoprotegerin (OPG) have been
shown to be associated with bone metastases of lung or breast.
However, the sensitivity of these markers is very low, suggesting
that they cannot be preferred over conventional bone scans in the
diagnosis of bone metastases. Greater sensitivity in the diagnosis
of bone metastases was found for urinary NTx (N-terminal
cross-linked telopeptide of type I collagen) and serum ICTP in
solid tumor patients, serum TRAcP-5b (tartrate-resistant acid
phosphatase type 5b) in patients with breast cancer, and serum
BSAP, PINP and OPG in prostate cancer patients (Singer and
David, 2008; Joerger and Huober, 2012).
Molecular Biomarkers
In bone tumors, molecular diagnostics can increase the accuracy
of the diagnosis and assist in subtyping bone tumors.
In their review, Szuhai et al. (2012) divide the genetic changes
found in sarcomas into three groups: sarcomas with specific
translocations (Ewing sarcoma, aneurysmal bone cyst), tumors
with gene mutations or amplifications (chondrosarcoma, fibrous
dysplasia, Chordoma), and sarcomas with genetic instability.
Frontiers in Pharmacology | www.frontiersin.org 2 April 2017 | Volume 8 | Article 150
fphar-08-00150 April 5, 2017 Time: 15:34 # 3
Evola et al. Biomarkers of Osteosarcoma, Chondrosarcoma, and Ewing Sarcoma
Different techniques can be used to detect cytogenetic
changes, such as banding and multicolor fluorescence in situ
hybridization, array comparative genomic hybridization (array
CGH), targeted detection techniques (FISH, RT-PCR) and
mutation detection techniques. Taking Ewing sarcoma as an
example, the EWS/FL1 fusion protein is a well-known oncogenic
factor in Ewing sarcoma. Recently, Robin et al. (2012) showed
that EWS/FLI1 mediates up regulation of EYA3. The reduction
of EYA3 protein has negative effects on the survival of Ewing
sarcoma. The authors thus proposed EYA3 as a novel mediator
of chemoresistance in Ewing sarcoma (Robin et al., 2012).
Yang et al. (2012) recently provided another example of
molecular targets for therapeutic use. The authors have shown
that all-trans retinoic acid (ATRA) inhibits the differentiation
and growth of human OS through the activation of SMAD,
suggesting a possible role for retinoic acid, in addition to classic
chemotherapy, in the therapy of OS (Yang et al., 2012).
Saini et al. (2012) through transcriptome, proteome and
Immunophenotyping for cell-surface markers, discover a
decrease of CD24, CD326 and CD44, and higher ABCG2 and
CBX3 expression in osteosarcoma TSC enriched cultures respect
to non-enriched samples. The authors thus identify ABCA5 as
a putative biomarker of TSCs and/or osteosarcoma (Saini et al.,
2012).
OSTEOSARCOMA
Osteosarcoma is the most prevalent malignant bone tumor
(Meyers and Gorlick, 1997), accounting for 30–80% of primary
skeletal sarcomas (Link and Eilber, 1989). The peak incidence is
at age 10–30 years (Bielack and Bernstein, 2005). Osteosarcomas
predominantly target the long cylindrical bones, including the
knee joint (approximately half of observations) and the humerus
(Mankin et al., 1996). Among the most affected are the femur,
tibia, humerus and, less frequently, shoulder blade, and bones
of the pelvis and skull (Enneking et al., 1980). Approximately
20% of patients present lung metastases at initial diagnosis and,
additionally, in 40% of patients metastases occur at a later
stage. Eighty percent of all metastases arise in the lungs, most
commonly in the periphery of the lungs, and exhibit resistance
to conventional chemotherapy (Kager et al., 2003; Harting and
Blakely, 2006; Bacci et al., 2008; Bielack et al., 2008; Hughes,
2009; Messerschmitt et al., 2009; Posthuma DeBoer et al., 2011).
The 5-year survival rate for OS patients with metastases is 20%,
compared to 65% for patients with localized disease, and most
deaths associated with OS are the result of metastatic disease
(Bielack et al., 2002; Eccles and Welch, 2007; Rodriguez et al.,
2008; Pradelli et al., 2009). Survival of patients has improved
with the discovery of new chemotherapies (Chou and Gorlick,
2006; Longhi et al., 2006; Perbal et al., 2009; Savitskaya et al.,
2012). The new biotechnological and pharmacological research
is directed on the use of markers serum tumor for treatment
of osteosarcoma. Several international study groups started a
multicenter study on the tumor markers (Fuchs et al., 1998; Ham
et al., 2000; Woodgate, 2000; Lewis and Nooij, 2003; Bielack et al.,
2009; Franke et al., 2011).
Serum Markers
Kaseta et al. (2007) analyzed the expression of genes bax,
caspase-8 and cytochrome c in subjects with osteosarcoma. They
performed an immunohistochemical analysis of 35 surgically
treated patients with primary OS and 18 tissue specimens from
non-malignant osseous lesions. The authors suggest that none
of the genes has a predictive role on survival, but the decrease
of 4-year disease-free survival in the group compared with the
control group, confirmed that more intensive adjuvant treatment
could reduce the recurrence rates of the disease (Kaseta et al.,
2007).
Contrary to previous hypotheses regarding c-erbB-2 and its
potential role as prognostic biological marker, the expression of
c-erbB-2 isn’t associated with the risk of metastases (Yalçin et al.,
2008).
Zhao et al. (2008) assess the distribution of ribonucleoprotein
hnRNP A2/B1 in the nuclear matrix in human osteosarcoma
MG-63 cells, saying that this nuclear matrix protein has an
important role on regulation of cell differentiation.
Luo et al. (2008) study the role of osteoblast in the
development of osteosarcoma.
The author affirms that levels of alkaline phosphatase (ALP),
Runx2, OSX, and osteopontin (OPN) were low in OS lines,
because most OS cells fail to complete terminal differentiation.
Their results suggest that alterations in osteoprogenitors
may disrupt the osteogenic differentiation pathway. Thus,
identifying potential differentiation defects in OS tumors would
make it possible to reconstruct the tumorigenic events in
osteoprogenitors and to develop rational differentiation therapies
for clinical OS management (Luo et al., 2008).
Based on the concept that glycoproteins and
glycosaminoglycans are an integral part of bone and prolonged
exposure to fluoride for long duration has been shown to
cause degradation of collagen and ground substance in bones,
Sandhu et al. (2011) analyzed serum fluoride, sialic acid, calcium,
phosphorus, and ALP levels in patients with osteosarcoma.
They found that, compared to control groups, serum sialic
acid concentration was significantly increased in patients with
osteosarcoma and, in a second study, in patients with other bone
tumors (Sandhu et al., 2011).
Guo et al. (2010) assesses the role of heat shock protein
gp96 (HSPgp96) in human osteosarcoma. HSPgp96, was mainly
expressed in the cytoplasm of osteoblastic sarcoma with less
differentiation. The authors affirm that the HSPgp96 has a role in
the pathogenesis of bone tumor, but the marker cannot be used in
determining the degree of malignancy and as a target for tumor
immunity (Guo et al., 2010).
Babkina et al. (2009) compare serum levels of endostatin,
placental growth factor (PlGF) and fibroblast growth factor-1
and -2 (FGF-1 and FGF-2) among patients of osteosarcoma and
a group of control patients; the author found increased levels
of PGF-2, PIGF and endostatin, while the levels of FGF-1 are
increased of 2.5 times (p= 0.004) (Babkina et al., 2009).
Yu et al. (2010) compare the expression of mitotic arrest
defective protein 2 (MAD2) in primary osteosarcoma and in
a control group by immunohistochemistry; the author notes
an increase of this protein in human osteosarcoma, especially
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in patients with metastasis and poor survival (Yu et al.,
2010).
Zhang et al. (2010) used gas chromatography mass
spectrometry approach and profiled small-molecule metabolites
to observe metabolic variations in urine and serum of patients
with osteosarcoma; the author notes a disrupted energy
metabolism, down-regulated lipid metabolism, dysregulated
sugar levels, up-regulated amino acid metabolism, increase of
glutathione metabolism and polyamine metabolism (Zhang et al.,
2010).
The expression and clinical significance of cysteine-rich
protein with Kazal motifs (RECK) was immunohistochemically
examined in 49 osteosarcoma patients by Xu et al. (2010). The
study confirmed that reduced RECK expression is a significant
factor of poor prognosis (p = 0.017). RECK status is a
useful prognostic factor in osteosarcoma and an independent
prognostic factor contributing to the determination of more
adequate therapy strategies for individual patients (Xu et al.,
2010).
Using RT-PCR and Western blot assays to detect IGF-1R
mRNA and protein expression in 26 osteosarcoma and non-
cancerous bone tissues, Wang et al. (2012) concluded that
insulin-like growth factor-1 receptor (IGF-1R) is an independent
prognostic marker for osteosarcoma patients and that an
increased expression of this molecule is correlated with metastasis
of osteosarcoma (Wang et al., 2012).
Observing that cysteine-rich intestinal protein 1 (CRIP1) has
a significant prognostic impact in gastric cancer, Baumhoer et al.
(2011) investigated its role in osteosarcoma. They analyzed 223
pre-therapeutic and well-characterized osteosarcoma samples for
the immunohistochemical expression of CRIP1 and correlated
their findings with clinic-pathological parameters including
follow-up, systemic spread and response to chemotherapy. The
expression of this factor is predominant in patients with longer
survival without metastases (Baumhoer et al., 2011).
Shimizu et al. (2012) performed a study to test the role of the
factors fibroblast growth factor-2 (Fgf2) or leukemia-inhibitory
factor (Lif) in the maturation of osteosarcoma cells. These factors
may reduce the osteogenic differentiation of osteosarcoma cells.
Also Fgf2 helps the proliferation and migration of neoplastic cells,
and alters the response of cells to drug therapy. The block of Fgf2
factor could modulate the progression of osteosarcoma (Shimizu
et al., 2012).
Lu et al. (2012) assess the role of WNT-5a and ROR2 markers
in development of various tumors through the expression of
WNT. The authors, by immunohistochemistry, observed the
expression of these two markers in patients with osteosarcoma
and osteochondroma. The authors say that contemporary
expression of both proteins is present in advanced stages and
promotes the diffusion of the tumor; moreover, gender, age and
the morphological variation do not have a significant role (Lu
et al., 2012).
Nunez et al. (2012) observed the expression of CD
138 (syndecan-1), normally found in epithelial tumors and
hematologic diseases, and affirm that the presence of this marker
in tumor bone cells does not exclude with certainty plasmatic
origin.
Jin et al. (2012) assess the role of gelsolin as a tumor marker
and therapeutic target in osteosarcoma. They characterized the
differential expression of protein biomarkers in osteosarcoma
serum, finding 58 significant protein spot features in
osteosarcoma sera. Further, Western blotting and enzyme
linked immunosorbent assay (ELISA) confirmed decreased
levels of gelsolin in the osteosarcoma serum samples (Jin et al.,
2012).
Nestin protein has been detected in various malignancies and
its expression correlates with advanced grade in some neoplasms.
Zambo et al. (2012) examined its possible role in osteosarcoma.
Using immunohistochemistry and immunofluorescence, they
evaluated nestin expression in tumor tissue samples from 45
patients with high-grade osteosarcomas. Nestin-positive tumor
cells were detected in all of the examined osteosarcomas. Using
immunofluorescence, high levels of nestin expression were
associated with poorer clinical outcomes. Despite the significantly
shorter survival rates observed in patients with elevated levels of
nestin expression, nestin does not appear to represent a powerful
prognostic marker that would be superior to conventional
methods (Zambo et al., 2012).
A study by Tan et al. (2012) evaluated preferentially expressed
the antigen of melanoma (PRAME), normally present in several
human cancers, assessing that this marker plays a role in
the proliferation and spread of bone tumor, although the
mechanisms are unknown. In addition, the author affirm that
this marker is associated with a poor prognosis and spread in the
lungs (Tan et al., 2012).
The chemokine, molecules involved in tumor genesis, have
been studied by Li et al. (2011). The author observed an increase
in serum levels in patients with osteosarcoma, particularly
CXCL4 and CXCL, and affirmed that the marker play a role in
clinical results and new studies are needed for the treatment (Li
et al., 2011).
Sharili et al. (2011) investigated the role of biomarkers Snail2,
commonly observed in skin tumors, in bone tumors. The author
observed that the expression of this marker is correlated with
the severity of the tumor and the risk of metastases. In addition,
the biomarker Snail2 is useful in the prognosis of bone tumors
(Sharili et al., 2011).
Interestingly, Funovics et al. (2011) assessed the pre-operative
serum C-reactive protein levels (CRP) in 79 patients undergoing
resection of an osteosarcoma. The author asserts that CRP is an
marker for survival in patients with high-grade tumor, and invites
further large-scale studies to confirm these results (Funovics et al.,
2011).
Genetic Markers
Perbal et al. (2008) evaluated the expression of CCN1 genes,
CCN2, and CCN3 in osteosarcoma; the author finds a
synchronous and ordered expression of these genes during
osteoblast differentiation in patients with osteosarcoma. In
addition, the author affirms that CCN1 and CCN2 genes haven’t
a role in the prognosis. In contrast, assessment for CCN3
expression levels at diagnosis may represent a useful molecular
tool for early identification of patients with different prognoses
(Perbal et al., 2008).
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Gillette et al. (2008) investigated a human osteosarcoma cell
line (OS 99-1), demonstrating the potentiality of this cell line to
form in vitro calcium nodules upon exposure to mineralization
inducing conditions and to represent an osteoblastic rather
than chondroblastic OS by displaying several osteoblast-specific
markers including collagen I, BSP, OC and ALP, whereas
chondroblastic markers (aggrecan and LINK) were undetectable.
However, this cell line provides a useful tool for investigating
the molecular mechanisms contributing to osteosarcoma and
may have the potential to serve as a culture system for studies
involving bone physiology (Gillette et al., 2008).
De Nigris et al. (2008) found that Y1 and VEGF/CXCR4 seem
to intervene in the pathogenesis of the malignant phenotype
of osteosarcoma by acting on cell invasiveness and metastasis
growth, because the deletion of the gene produces a lower
involvement of the cells by the tumor and a lower spread.
Zuffa et al. (2008) investigated the effect of TP53 (tumor
protein 53, p53) on the genetic stability in patients with
osteosarcoma. The author notes that the protein protects the
DNA of cells, although are not known the mechanisms of
protection exactly (Zuffa et al., 2008).
Wei et al. (2008) analyzed the c-kit gene in patients affected by
osteosarcoma; the author notes that gene alteration of the protein
is a prognostic marker of the tumor; moreover, exons 11 and 17
can’t be considered for the treatment of cancer through reduction
of c-kit tyrosine kinase activity.
Nathan et al. (2009) observed, through a molecular analysis
of cell line OS1, a genome instability after mutations that affect
the function of the transcription factor Runx2. The author
asserts that this cell line allows to identify possible molecular
abnormalities that transform the osteoblast into cancer cells
(Nathan et al., 2009).
The role of transcriptional regulators Oct-4 in osteosarcoma
has been studied by Levings et al. (2009). According to the author
this genetic marker plays a biological role in the proliferation and
spread of cancer (Levings et al., 2009).
The expression of Mir-34s was reviewed by He et al. (2009)
into two categories of osteosarcoma: U2OS (p53 +/+) and
SAOS-2 (p53 −/−). The author states that the action of miR-34s
is p53-dependent, and causes alteration of proliferation and
apoptotic process. He et al. (2009) observed a reduced expression
and inactivation of miR-34 gene in a group of osteosarcomas.
Yang J. et al. (2010) evaluated the role of the WWOX gene
and, through comparative genomic hybridization, showed how
the elimination or downregulation affects the survival of patients
with osteosarcoma; also the author believes that the phenotypic
alteration affects the early phases of the disease.
Analyzing blood samples of 168 osteosarcoma patients, Hu
et al. (2010) used PCR amplification and DNA sequencing to
determine the TGFBR1∗6A variant, a dominant polymorphism
of the transforming growth factor β receptor 1 (TGFBR1). Their
conclusion was that TGFBR1∗6A is associated with increased
susceptibility to, and metastasis diffusion of, osteosarcoma (Hu
et al., 2010).
Mirabello et al. (2010) report an association study of common
single-nucleotide polymorphisms (SNPs) across 8q24 to explore
the role this region may play in osteosarcoma risk. The 8q24
chromosomal region contains several loci that are associated with
the risk of many different cancers. The study suggested that
several SNPs in 8q24 may be associated with osteosarcoma, but
the susceptibility observed was modest (Mirabello et al., 2010).
Bcl-xL, a member of Bcl-2 protein family functioning as
dominant regulators of apoptotic cell death, has been reported
to play important roles in malignant transformation and tumor
development. Wang et al. (2010) studied the expression of
Bcl-xL in osteosarcoma with therapeutic aims. The author,
through many genetic techniques, compare the expression of
this gene in tumor and non-tumor cells. An increase of
Bcl-xL mRNA was observed in cancer cells with metastases
compared to non-metastatic cells; also the expression of gene
was significantly higher in tissues with tumor compared to
healthy ones. Therefore, the author believes that the increase
of the expression of Bcl-xL mRNA has a role in the diffusion
of osteosarcoma and can be a useful molecular target for the
treatment (Wang et al., 2010).
Based on many papers reporting that the reduction of
expression of Fas protein is correlated to a higher risk of
lung metastases and arsenic trioxide (ATO) may promote cell
apoptosis in cancers. Yang G.F. et al. (2010) evaluated the role
of ATO and the degree of expression of the Fas protein of
human osteosarcoma cells (Saos-2 cell line); the author affirms
that ATO reduces cell proliferation according to the dose and
time and increased the expression of the Fas protein, although
other mechanisms are interested in this process (Yang G.F. et al.,
2010).
Wang et al. (2011), assert that the + 49G/A polymorphism
of cytotoxic T-lymphocyte antigen-4 (CTLA-4), a molecule that
decreases the immune response mediated by T-cells, promotes
the development of osteosarcoma.
Lockwood et al. (2011) performed an analysis of DNA in
osteosarcoma tumor samples. The overexpression of cyclin E1
was linked to potential prognostic and therapeutic implications
(Lockwood et al., 2011).
A study performed by the Massachusetts General Hospital
group asserts that miR-199a-3p is involved in proliferative
process of osteosarcoma. The restoration of this marker may
provide therapeutic benefits in osteosarcoma. MicroRNAs
(miRNA, miR) play an important role in cancer cell growth
and migration. However, the potential roles of miRNAs in
osteosarcoma remain largely uncharacterized. By applying a
miRNA microarray platform and unsupervised hierarchical
clustering analysis, they found that several miRNAs have
altered expression levels in osteosarcoma cell lines and tumor
tissues when compared with normal human osteoblasts.
Three miRNAs, miR-199a-3p, miR-127-3p and miR-376c,
were significantly decreased in osteosarcoma cell lines
compared to osteoblasts, whereas miR-151-3p and miR-191
were increased in osteosarcoma cell lines (Duan et al., 2011)
(Figure 1).
A preliminary study by Folio et al. (2011) supports the
hypothesis that overexpression of Cortactin (CTTN) gene,
contained in the 11q13 amplicon, is involved in osteosarcoma
carcinogenesis. The potential of cortactin overexpression as
a biomarker for osteosarcoma is, in fact, consolidated and
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FIGURE 1 | MiRNA genes that play a role in the development and progression of Osteosarcoma.
transcriptomic profiling has shown cortactin to be overexpressed
in pediatric osteosarcoma. The CTTN represents, according to
the author, a valid biomarker for cancer (Folio et al., 2011).
Shen et al. (2012) examined the expression and localization
of hArgBP2 in osteosarcoma MG-63 cells. After the successful
construction of a recombinant plasmid of hArgBP2 gene,
they identified the expression of GFP-hArgBP2 fusion mainly
localized in the cytoplasm and perinucleus of MG-63 cells. The
protein was identified and isolated using GFP antibody (Shen
et al., 2012).
Yang et al. (2011), using microarray-based comparative
genomic hybridization (aCGH), reported for the first time
That vascular endothelial growth factor (VEGF) pathway genes,
including the VEGFA protein, is overexpressed and play a role in
poor prognosis and reduced survival in osteosarcoma (Yang et al.,
2011).
Chen et al. (2012) used immunohistochemical staining in
serial sections of the osteosarcoma analyzed to investigate
expression patterns of IGF2 and IMP3 and their relationship with
angiogenesis in the tumor. The author states that the increased
expression of IGF2 and IMP3 can promote tumor angiogenetic
processes (Chen et al., 2012).
Prognostic Factors
Western blot analysis showed that expression of CRM1 (an
intermediary involved in the transport of essential molecules of
the cell, such as proteins and messenger RNA) was significantly
increased in osteosarcoma compared with normal tissues (Yao
et al., 2009).
Won et al. (2009) analyzed the role of Runx2 protein
in bone tumor; the author affirms that an increase in
its expression results in an higher risk of osteosarcoma
spread, and therefore considers the protein a valid prognostic
marker.
Genetic alterations of glutathione S-transferase supergene
family can change the body’s defense mechanisms to carcinogens,
increasing the risk of cancer and pharmacoresistance.
Salinas-Souza et al. (2010) investigated the genotype
frequencies of GSTM1, GSTT1 and GSTM3 genes in 80
osteosarcoma patients and 160 normal control participants,
and also the influence of these polymorphisms on the
clinical outcome of osteosarcoma patients. They concluded
that GST polymorphisms may have a role in treatment
response and osteosarcoma progression (Salinas-Souza et al.,
2010).
EWING SARCOMA
Ewing’s sarcoma is one of the few solid tumors for which the
underlying molecular genetic abnormality has been described:
rearrangement of the EWS gene on chromosome 22q12 with an
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ETS gene family member. These translocations define Ewing’s
sarcoma family tumors (ESFT) and provide a valuable tool for
their accurate and unequivocal diagnosis. They also represent
ideal targets for the development of tumor specific therapies.
EWS-FLI Gene
Ewing’s sarcomas is a particular type of bone tumor due to
translocations of genes with formation of EWS-ETS fusion
proteins, in particular EWS-FLI, a transcription factor more
involved in the neoplasm. Since the etiology of Ewing’s sarcomas
is unknown, several models have been developed with the aim to
identify EWS-FLI target genes.
Hancock and Lessnick (2008) through a meta-analysis have
identified the genes that are altered by EWS-FLI. This study
allowed us to confirm the involvement of known genes and the
identification of new genes. The comparison of the data from
this study and those published on mesenchymal stem cells has
allowed to affirm that these cells are potential precursors of tumor
(Hancock and Lessnick, 2008).
Potikyan et al. (2008) detect a fibroblast, called IMR-90, which,
through genetic modification, expresses EWS/FLI1; the author
found that these cells go to neoplastic degeneration following the
expression of this transcription factor.
Through a genome-wide high-resolution analysis, Savola
et al. (2009) identify genetic areas with more involvement
by transcription factor EWS/FLI1. In most cases, the changes
affect the chromosomes 1q, 2, 8,9p, 12, end 16q. The authors
conclude that this method could be an effective way of identifying
chromosome regions and new genes affected by cancer (Savola
et al., 2009).
Bachmaier et al. (2009) notes that the alteration of
glycosylation of EWS-FLI1 allows to modify his tumor action
and, therefore, is a useful aspect for the pharmacological
treatment; the author notes that the glycosylation and
phosphorylation of EWS-FLI1 modify the molecular weight
and then the functionality of the transcription factor. Through
mutation analysis, O-GlcNAcylation was traced to Ser/Thr
residues of the amino-terminal EWS transcriptional-activation
domain. Metabolic inhibition of the hexosamine biosynthetic
pathway abrogated O-GlcNAcylation of EWS-FLI1 and
interfered specifically with transcriptional activation of the
EWS-FLI1 target Id2 (Bachmaier et al., 2009).
Guillon et al. (2009) investigated EWS-FLI1-bound DNA
sequences in two Ewing cell lines and showed that the
transcription factor preferentially binds two types of sequences
including consensus ETS motifs and microsatellite sequences.
Moreover, in reporter gene experiments, the transcription
activation is highly dependent on the number of repeats that
are included in the construct. Importantly, in vivo EWS-FLI1-
bound microsatellites are significantly associated with EWS-
FLI1-driven gene activation. Together, these results indicate the
likely contribution of microsatellite elements to long-distance
transcription regulation and to oncogenesis (Guillon et al., 2009).
Szuhai et al. (2009) through the use of instruments to study the
cellular genome, showed a translocation that is not known which
affects both EWSRI and NFATc2. The involvement of NFATc2, a
transcription factor, determines an abnormal immune response,
secondary to altered function of T-cell (Szuhai et al., 2009).
Hypoxia is a major factor of cell regulation in bone tumors,
through the activation of transcription factor “hypoxia-inducible
factor-1” (HIF-1); Aryee et al. (2010) studied the effect of hypoxia
on cell lines of ESFTs in vitro. The author affirms that the hypoxia
allows to control EWS-FLI1 expression, resulting in variability of
clinical and prognostic features in tumor (Aryee et al., 2010).
Vural et al. (2011) studied CD99 expression associated with
EWS/FLI1 translocations in order to define the clinical and
prognostic results of bone tumor. The author found a statistically
significant relationship in CD99 expression in Ewing’s sarcoma,
and therefore considers that this marker has a role in the
diagnosis and prognosis of cancer (Vural et al., 2011).
The Rizzoli Experience, conducting a molecular diagnosis
of EFT over 4 years (2006–2009), was reported in 2011. The
authors study the genome of a group of patients with Ewing’s
sarcoma. The authors find different types of genetic abnormalities
as a result of translocation of chromosomes: five forms of
EWSR1-FLI1, three forms of EWSR1-ERG, and one EWSR1-FEV
(Gamberi et al., 2011).
Erkizan et al. (2011) identified a potential scaffold for Ewing’s
sarcoma, through the isolation of 27 binding peptides; the author
found that the peptide ESAP1 shows a high binding to EWS-FLI1
in bone cancer. The minimal interaction region of ESAP1 was
characterized and the lysine residues were found to be critical for
cellular cytotoxicity. ESAP1 reduces the transcriptional activity
of EWS-FLI1 and also disrupts cell cycle kinetics in Ewing tumor
cells (Erkizan et al., 2011) (Figure 2).
Other Genetic Markers
Douglas et al. (2008) investigated whether tumors of the
Ewing sarcoma family express the BMI-1 gene, and whether
it functions as an oncogene in this highly aggressive group
of bone and soft tissue tumors. Their data showed that BMI-
1 is highly expressed by ESFT cells and that, although it
does not significantly affect proliferation or survival, BMI-1
actively promotes anchorage independent growth in vitro and
tumorigenicity in vivo. The authors, moreover, found that BMI-1
promotes the tumorigenicity of both p16 wild-type and p16-null
cell lines, demonstrating that the mechanism of BMI-1 oncogenic
function in ESFT is, at least in part, independent of CDKN2A
repression. The data suggests a pivotal role for BMI-1 in ESFT
pathogenesis (Douglas et al., 2008).
A recent statistical methodology, called ICAN, allows to select
genes that play a role in the prognosis and progression of
tumors in studies with small samples, was reported by Bennani-
Baiti et al. (2010) and tested in Ewing’s sarcoma (ES). Through
this methodology the author affirms that CXCR4 expression
increases the risk of tumor metastases, while CXCR7 expression
is associated with shorter survival.
Some studies have shown that the EWS-ETS fusions, due
to genetic changes, does not have a prognostic significance or
Ewing’s sarcoma. Consequently, in an integrative genomic study
of 105 ES tumors, Mackintosh et al. (2012) affirms the prognostic
significance of 1QG and CDT2 expression in cancer, noting that
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FIGURE 2 | EWS-FLI cause gene specific activation and repression.
this marker can be used in tumor therapy selectively (Mackintosh
et al., 2012).
Serum Markers
In Ewing’s sarcoma is present an increased expression of
VEGF165 isoform; according to Huang et al. (2012) the
reduced CAPER-α expression by EWS/FLI-1 causes an increased
expression of this isoform.
An interesting study by the University of Texas group
suggested that modulation of receptor activator NF-κ B (RANKL)
by vascular endothelial growth factor-165 (VEGF165) can result
in the activation of osteoclastic cells in Ewing’s tumor, through
RANKL gene expression, and lead to the destruction bone.
Based on the fact that VEGF165 induced osteoclast formation
in murine bone marrow cells, the authors found that RANKL
was unregulated in a dose- and time-dependent manner when
ES cells were incubated with recombinant VEGF165 (Guan et al.,
2009).
The role of the polycomb protein BMI-1 in Ewing’s sarcoma
prognosis was studied by Cooper et al. (2011) the author has
compared by genetic analysis two samples of bone tumors
with an increased or decreased expression of this marker. They
concluded that Ewing sarcoma family tumors (ESFT) which do
not overexpress BMI-1 represent a novel subclass with a distinct
molecular profile and altered activation of, and dependence on,
cancer-associated biological pathways (Cooper et al., 2011).
FLI-1 has been described as a useful marker for Ewing
sarcoma, particularly when hematolymphoid markers are
negative. Using a monoclonal FLI-1 antibody, Lee et al. (2011)
evaluated nuclear immunoreactivity in tumor cells in 10 small
cell osteosarcomas, 10 mesenchymal chondrosarcomas, and
8 Ewing sarcomas, together with a number of other small,
round, blue cell tumors. Their results showed that, in contrast
to Ewing sarcoma, small cell osteosarcoma and mesenchymal
chondrosarcoma lack FLI-1 immunoreactivity. FLI-1 is therefore
useful in the differential diagnosis of small round blue cell tumors
of the bone (Lee et al., 2011).
Considering Ewing sarcoma (ES) to be a systemic disease,
Ash et al. (2011) used multiparameter flow cytometry (MPFC)
to detect ES cells in the bone marrow (BM) of ES patients
at diagnosis and to evaluate the prognostic significance of
CD56 expression in BM samples. The authors observed that the
cells had a contemporary expression of CD99-CD90-CD45, and
therefore considered Ewing’s sarcoma a systemic disorder. Their
conclusion was that CD56 expression could be used to identify ES
patients (Ash et al., 2011).
Machado et al. (2011) assessed, by genetic analysis, the role
of epithelial markers in Ewing’s tumor; the author to show
the presence of epithelial markers used antibiotics and an
immunohistochemical study in tumor cells. The authors say a
statistically significant relationship between the expression of the
markers and epithelial cell variants of the tumor is not present,
even if they claim that an increased expression is present in these
tumors and therefore can be regarded in the diagnosis of the
disease (Machado et al., 2011).
Do et al. (2008) studied the correlation between HuR protein, a
protein intended to stabilize the mRNAs, and Cyclooxygenase-2,
an enzyme involved in the spread of tumors, in Ewing’s tumor; the
author, who supposed that HuR can stabilize the mRNA of COX-
2, does not observe a simultaneous increase of the expression
of HuR protein and Cyclooxygenase-2 in cancer cells; also Do
et al. (2008) believe that that relationship is indirectly evaluated
by observing the mRNA stabilization.
CHONDROSARCOMA
Chondrosarcomas are malignant cartilage tumors. The annual
incidence is 1 in 1,000,000 people, with greater involvement of
people with ages between 30 and 60; the disease affects more
frequently the pelvis and lower limbs (Hogendoorn et al., 2010).
We can distinguish between primary and secondary
chondrosarcomas. The chondrosarcoma may develop from
other bone tumors such as osteochondroma and enchondroma.
In these cases they can occur as multiple lesions.
There are four different histologic variants of chondrosarcoma
(Fletcher and Unni, 2002):
(1) Mesenchymal chondrosarcoma is a highly malignant
tumor, histologically similar to Ewing’s sarcoma, with foci
of cartilaginous differentiation. This very aggressive type
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of chondrosarcoma has a high risk of local recurrence and
distant metastasis.
(2) Dedifferentiated chondrosarcoma. These are aggressive
neoplasms and have a poor prognosis.
(3) Clear cell chondrosarcomas are low-grade tumors. They
typically involve the epiphyseal end of a long bone.
Radiographs show a lytic defect at the epiphyseal end
of long bones which is sharply demarcated with sclerotic
margins. They carry a low recurrence rate and a good
prognosis with wide resection.
(4) Extraskeletal myxoid chondrosarcoma, is a slow-growing
tumor characterized, histologically, by prominent myxoid
degeneration and a prolonged course, despite the high
incidence of local recurrence (Yasuda et al., 2012).
Extraskeletal myxoid chondrosarcoma has been considered
by the World Health Organization as a differentiated
tumors in cancer classification (Fletcher and Unni, 2002).
Chondrosarcomas can be classified into three histological
grades.
Grade I (low grade) – hyperchromatic plump nuclei of uniform
size and cytology very similar to enchondroma.
Grade II (intermediate grade) – Increased cellularity;
hypercromasia; distinct nucleoli and foci of myxoid alteration.
Grade III (high grade) – with increased cellularity and nuclear
atypia, occasional giant cells, abundant necrosis and presence
of mitosis.
The higher grade tumors are the most malignant. Grade I
lesions rarely metastasize, whereas 10–15% of grade II lesions and
more than 50% grade III lesions metastasize.
Low-grade chondrosarcomas resemble benign cartilaginous
tumors, and it is difficult to differentiate between the two lesions
on the basis of histological features alone. Understanding the
difference between a chondrosarcoma and its benign counterpart
is crucial for the prognosis, as evidenced by several authors and
by Weber in her case report (Weber and Raymond, 2002).
The role of biochemical and genetic markers in diagnosis,
prognosis, and treatment of chondrosarcoma is unclear.
Genetic Markers
Hallor et al. (2009) found a similar pattern of genomic imbalances
in an high percentage (90%) of 67 chondrosarcoma cases. The
author found deletions of loci at the level of CDKN2A, EXT1, and
EXT2 genes, who are interested in the development of the disease.
The alteration of specific gene regions suggests a potential role for
genetic markers in diagnosis and prognosis of chondrosarcomas
(Hallor et al., 2009).
Szuhai et al. (2012) reported that most peripheral
chondrosarcomas had a higher proliferation rate on Ki-67
immunohistochemistry and that they were associated with loss
of heterozygosity at many loci.
According to the ESMO/EUROBONET Working Group,
the overexpression of p53 protein, 17p1 alterations, and
TP53 mutations in high-grade chondrosarcomas suggest
that the p53 mutation is a late event involved in tumor
progression. Amplification of 12q13 and loss of 9p21 are genetic
aberrations found in conventional chondrosarcomas. The loss of
INK4A/p16 expression was shown to be restricted to high-grade
chondrosarcomas, suggesting it plays a role in tumor progression
(Hogendoorn et al., 2010).
Rozeman et al. (2005) showed that higher expression of
PTHR1 and Bcl-2 was associated with increasing histological
grade in chondrosarcoma, suggesting its involvement in tumor
progression. Instead, PTHrP signaling is not important in the
malignant transformation of enchondroma (Rozeman et al.,
2005).
A recent study by Liang et al. (2012) investigated
overexpression of Aurora Kinase A and B in chondrosarcoma
and their relevance to prognosis. The expression of Aurora
Kinase A and B was significantly higher in chondrosarcoma than
in chondroma (p < 0.01). The author evaluates the expression
of Aurora Kinase A and B in patients with recurrence and
metastasis, and found that the marker expression is significant
in these patients than in the control group (p > 0.05). Also
observes that the expression of the marker is lower in low-
grade tumors compared to medium and high grade tumor
(p < 0.01). The sex and age does not show a statistically
significant correlation with tumor prognosis. Liang et al. (2012)
assert that the expression of Aurora Kinase A and B influences
patient survival significantly. However the use of these markers
as prognostic factors needs further study. They also propose
Aurora Kinase A and B as therapeutic targets (Liang et al.,
2012).
Amary et al. (2011) identified somatic heterozygous
isocitratedehydrogenase 1 (IDH1) hot spots (R132C and
R132H) or IDH2 (R172S) as mutations present in cartilaginous
tumors but not in other mesenchymal tumors.
In their review, Szuhai et al. (2012) identified several active
signaling pathways for central chondrosarcoma, including pRB
(61,62), IHH/PTHLH/Bcl-2 (63e66), Src, Akt, and PDGFR with
no effect of imatinib, IGF, or estrogen signaling, together with
hypoxic and glycolytic pathways and the overexpression of the
Bcl-2 family.
Signaling in dedifferentiated chondrosarcomas was also
studied by Rozeman et al. (2009) in a case series of 16
dedifferentiated chondrosarcomas. The author compares
peripheral chondrosarcomas with secondary peripheral
chondrosarcomas and notes the lack of CD44v3 and lower BCL-
2 expression. Authors found improved survival in peripheral
dedifferentiated chondrosarcomas with PAI-1 expression. They
concluded that in dedifferentiated peripheral chondrosarcomas
PAI-1 might also be of interest as a prognostic marker both
in peripheral and in central dedifferentiated chondrosarcoma
(Rozeman et al., 2009).
Various authors have studied the role of extracellular receptor
kinase proteins (ERK) in chondrosarcoma. Chandhanarat
et al. (2012) analyzed the role of MAPK/ERK signaling
in osteosarcoma, Ewing sarcoma and chondrosarcoma and
affirms that there is no data on the effectiveness of the
MAPK/ERK therapy for chondrosarcomas, although there are
studies in the literature that show positive results in the
treatment of metastatic osteosarcomas (Chandhanarat et al.,
2012).
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Sun et al. (2010) report that chondrosarcoma cell invasion is
increased by hypoxia, induced CXCR4 and MMP1 expression,
and is mediated by HIF-1a and ERK. With CXCR4 blocking,
both invasion and MMP1 can be inhibited. Thus, the authors
suggest the CXCR4/SDF1 signaling as a therapeutic target for
chondrosarcoma (Sun et al., 2010).
In 2009, the same authors found that reduced expression
of HDAC4 in chondrosarcoma cells increases expression of
Runx2, leading to increased VEGF expression and in vitro
angiogenesis. Thus, both hypoxia and dysregulated expression
of a developmental pathway are causes of increased VEGF
expression in chondrosarcoma (Sun et al., 2010).
Pedrini et al. (2011) analyzed the role of EXT mutations
in 529 patient with multiple hereditary exostoses. Malignant
transformation was observed in 5% of patients, and no
evidence of association between chondrosarcoma onset and EXT
mutation, sex, severity of disease or number of lesions was
detected (Pedrini et al., 2011).
Tirino et al. (2011) states that CD133 marker is useful in the
isolation of stem cells in bone tumors.
Zenmyo et al. (2010) studied the expression of GADD45b in
chondrosarcoma and its role in tumor progression. The author
says that GADD45b expression is inversely proportional to the
histological grade of the bone tumor, and therefore, this marker
is useful to study the degree of differentiation (Zenmyo et al.,
2010).
Biological and Molecular Markers
Although chondrosarcomas are considered to be chemo- and
radio-resistant, Jamil et al. (2010) reviewed and proposed
different molecular and genetic therapeutic targets for
chondrosarcoma. The author states that methoxyestradiol
reduces angiogenesis and cell proliferation, and therefore,
this marker may lead apoptosis in chondrosarcoma’s cells and
arrest the progression of the disease. PEDF has been shown to
increase cellular apoptosis in chondrosarcoma. Jamil notes that
Epigallocatechin-3-gallate has an anti-inflammatory action and
positive effects in the treatment of chondrosarcoma. The author
assesses the role of peroxisome proliferator-activated receptor
gamma, a nuclear receptor that regulates the proliferation and
apoptosis in different cancers; according to Jamil et al. (2010) this
marker is present in chondrosarcoma and therefore can be used
in the identification of illness.
Meijer et al. (2011) evaluated the role of aromatase and
estrogen receptor alpha in bone tumor proliferation; the authors
suggest that the presence of both markers in tumor cells in
patients with chondrosarcoma indicates a higher risk of cell
proliferation. But in vitro and pilot in vivo studies have shown
no effect of estrogen-signaling inhibition on tumor growth. Thus,
ESR1 could be a diagnostic or a prognostic marker but has little
role in therapy (Meijer et al., 2011).
In recent years, various authors have examined the role of
COX-2 expression in chondrosarcoma with its implications for
therapy and, in particular, for prognosis. Schrage et al. (2010)
analyzed COX-2 expression in cartilaginous tumors. They
confirmed the expression of COX-2 in 65% of chondrosarcomas.
They also found high COX-2 protein expression was
mainly found in solitary peripheral chondrosarcoma and in
enchondromatosis-related central chondrosarcoma, which was
confirmed by qPCR. They emphasize the potential role of
celecoxib in treatment (Schrage et al., 2010).
Nakagawa et al. (2010) reported that there was a significant
association of nitrotyrosine, COX-2 and CD34 with histological
grades of chondrosarcoma, suggesting that these markers have a
role in patient survival.
Cintra et al. (2011) investigated the role of COX-2 expression
and angiogenetic factors in chondrosarcoma progression. The
authors observed that a high COX-2 expression adversely affects
patient survival and a positive correlation between CD34 and
COX-2 expression, which confirms the relationship between
COX-2 and angiogenesis, suggesting a possible role for this
marker in patient prognosis (Cintra et al., 2011).
Ariizumi et al. (2010) investigated the role of lymphatic
marker podoplanin in chondrosarcoma. In their series,
podoplanin was expressed strongly (10/10) by chondrosarcomas.
Therefore, they concluded, this marker is useful for identification
bone cancer (Ariizumi et al., 2010).
Papachristou et al. (2008) studied the role of Integrin-
linked kinase, α and β-parvin, Mig-2 in chondrosarcoma. These
molecules allow cell attachment to the matrix, motility and cell
growth. According to the author these biomarkers are particularly
expressed in this bone cancer and thus play a role in the
progression and prognosis of the disease (Papachristou et al.,
2008).
CONCLUSION
During growth the most prevalent kind of tumor are
osteosarcoma, chondrosarcoma, and sarcoma of Ewing.
Current knowledge of the molecular biomarker involved in each
type of tumor has led to better approaches in the treatment.
Molecular markers increase the accuracy of the diagnosis and
assist in subtyping bone tumors, thus improving the quality of
life of patients. This review had the objective to summarize the
biomarkers are more interested in these three types of bone
tumors.
FUTURE PERSPECTIVES
Despite the large progress in the field, as the discovery of
new markers (sCD30 and sCD40L), many challenges are still
ahead. The search for biomarkers for non-invasive diagnosis of
bone tumors is currently an area research interests. One of the
most important aspects will be the identification of microRNAs
involved in bone tumors. MicroRNAs are a group of small non-
coding RNAs circulating in blood of patients, that play a role
in post-transcriptional gene expression in normal and disease
physiologies, even if its molecular mechanisms still remain
elusive. MicroRNAs have been considered potential biomarkers
and can be used for diagnosis, prognosis, and targeted treatment
of neoplastic bone disease.
The differential expression profiles of miRNAs can be
used as promising diagnostic and prognostic biomarkers of
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osteosarcoma, chondrosarcoma, and Ewing sarcoma; miRNAs
play a positive role in the progression of bone tumors by
regulating proliferation, invasion, metastasis, apoptosis and
angiogenesis. The identification of more specific non-invasive
biomarkers could help the treatment of bone tumors in the
future.
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